Showing results (1351-1360 of 1,403) with videos related to

Sort By:
Pageof 141
The British Journal of Dermatology|September 5, 2024
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024Michael R Ardern-Jones, Sara J Brown, Carsten Flohr, et al.
Journal of Extracellular Vesicles|December 8, 2023
MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle researchFabrice Lucien, Dakota Gustafson, Metka Lenassi, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
Trials|August 3, 2025
A mechanism-based group psychotherapy approach to aggressive behavior (MAAP) in borderline personality disorder: a multicenter randomized controlled clinical trialChristine Sigrist, Andreas Bechdolf, Katja Bertsch, et al.
Cell Reports|March 1, 2018
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingJonathan D Finn, Amy Rhoden Smith, Mihir C Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2006
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Jens R Sydor, Emmanuel Normant, Christine S Pien, et al.
Current Oncology (Toronto, Ont.)|June 4, 2020
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomesS Ahmed, L Barbera, S J Bartlett, et al.
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Pageof 141